In suitable patients, the NobleStitch system is potentially the best solution for PFO closure.
Fountain Valley, CA (PRWEB) July 09, 2014
Nobles Medical Technologies II (NMT2) today announced that Dr. Michael Mullen (Consultant Cardiologist at the University College Hospital and Member of the NMT2 clinical Advisory Board) presented positive results for the 1-year follow up of patients treated with NobleStitch EL PFO Closure System. NMT2 received positive reviews from Cardiologists and Industry at the Congenital & Structural Interventions Congress in Frankfurt, Germany. The CSI congress is the most significant meeting for NMT2 with over 800 of the top interventional cardiologists in structural heart coming together to share the latest in structural heart interventions.
Dr. Mullen presented his experience with the NobleStitch EL on cases performed at the University College Hospital in London. Dr. Mullen commented, “In suitable patients, the NobleStitch system is potentially the best solution for PFO closure. This is the only system that can achieve closure without leaving a device behind, without the risk of migration, erosion, perforation or atrial fibrillation,” side effects that may be associated with standard PFO closure devices.
Prof. Anthony Nobles, CEO of NMT2 commented, “The response to Dr. Mullen’s data from the cardiology community was very positive. As indications for PFO closure increase concerns remain about the long-term adverse effects of current synthetic PFO closure devices (Metal framed “Umbrella’s”), the demand for a system that facilitates closure with limited or no impact on normal physiology or anatomy increases. The NobleStitch EL PFO closure system satisfies these criteria and represents a significant advance in PFO closure technology with the potential to broaden the number of patients that will benefit from having their PFO closed.”
Ben Brosch, President of NMT2 commented, “The NobleStitch EL is CE marked for PFO Closure and cardiovascular suturing in the European Union. Nobles Medical Technologies II has expanded supplying the NobleStitch EL in the UK, Sweden & Germany and expects to launch throughout Europe, China and Kazakhstan over the next several months.”
About Patent Foramen Ovale (PFO)
A PFO is a tunnel that exists between the left and right atrium of the heart. The tunnel, which is part of the normal fetal anatomy, should close shortly after birth. In 27% of the population the tunnel never closes. This tunnel can then allow clots and other chemicals to pass from the right to the left side of the heart freely bypassing the filter of the lungs. These clots and chemicals can cause strokes and other conditions such as severe migraines.
About the NobleStitch EL System
Nobles Medical Technologies II's NobleStitch EL is a catheter based system that allows a physician to place a suture in the PFO tunnel in the heart through a percutaneous puncture in the leg, in many cases under a local anesthetic in a catheter lab rather than an operating room. This eliminates the need for open-heart surgery or placement of a large metallic implant in the heart. The NobleStitch is not a “device” or mechanical implant, it only places a simple polypropylene suture in the heart. By closing the hole or PFO, the therapy will reduce or eliminate the shunting from the right to the left side of the heart allowing the lungs to filter the clots and other chemicals from making it to the brain, potentially halting strokes and severe migraines and enabling patients to live a higher-quality life.
The NobleStitch EL is CE marked for Cardiovascular suturing including PFO closure and is FDA 510(k) cleared for vascular stitching in general surgery, including endoscopic procedures.
About Nobles Medical Technologies II
Nobles Medical Technologies II is a global structural heart company devoted to improving life through the development of its products and technologies. Nobles Medical Technologies II is focused on suture based solutions for the septum.
Visit Nobles Medical Technologies II, http://www.noblesmedicaltechnology.com.